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Introduction: It is important to identify those patients with OSA who are likely to benefit from
long term CPAP, not only for symptomatic relief, but also potentially to reduce vascular
morbidity and mortality, but are unlikely to adhere to treatment. We have validated a model
which we developed previously for predicting long term compliance with CPAP using data after
a 2 week trial.
Methods: The model was applied retrospectively to patients undergoing a trial of CPAP. Pre-
dicted outcomes were compared with the actual outcomes.
Results: Prediction equation was applied to 448 patients [77% males, Age 53  11 years, ESS
14  4, AHI 37  24]. Of 407 patients included in the study 333 were issued a CPAP and 74
declined long term CPAP. At one year, 81% patients were using CPAP at least 2 h and
70% > 4 h. A score >50% from the equation was associated with a high probability of CPAP
usage at one year. 295 patients had a probability score of >50% and of them 84% were using
CPAP satisfactorily at 1 year. The sensitivity in identifying compliers was 91%. Of the 112
patients with a score 50%, 38 opted to accept CPAP and 60% of them were still using it at
1 year.
Conclusions: This simple equation has now been validated to be highly sensitive in identifying
long term compliers and it also identifies those with worse compliance. This group could be
targeted for a more intensive follow up regime with the aim of improving their compliance.
ª 2012 Elsevier Ltd. All rights reserved.of Respiratory Medicine, Sleep and Non-invasive Ventilation Services, St. James’s University Hospital,
Kingdom. Tel.: þ44 113 2065863; fax: þ44 113 2066042.
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(ESS), Apnoea Hypopnoea Index (AHI), Oxygen DesaturationObstructive Sleep Apnoea Syndrome (OSAS) is common and
has a prevalence of 2e4% in the general adult population.1
It is under diagnosed and under treated.2e4 Daytime intel-
lectual and physical function are affected and the inci-
dence of systemic hypertension, diabetes, cardiovascular,
and cerebrovascular disease increased.5e12 Patients with
OSAS have been shown to be at increased risk of traffic
accidents.13 Continuous positive airway pressure (CPAP) is
recommended as first-line therapy for most patients with
symptomatic OSAS and has been shown to improve sleep
quality, reduce daytime sleepiness, and enhance quality of
life.14 Long term treatment with CPAP might reduce
vascular morbidities and hence it is important to identify
patients who might have problems with compliance in the
long term.15e17
Instituting CPAP treatment usually includes a short trial
of CPAP lasting between 2 and 4 weeks. During this period
pressure is titrated and problems, particularly with the
mask are addressed. Patients then make a decision about
whether they wish to continue it. However long term
compliance with CPAP is variable and studies quote non-
compliance rates as high as 50% by 1 year.18 Organizing
CPAP trials and issuing machines is an expensive and time
intensive process. Various attempts have been made to
predict and identify factors which predict short and long
term compliance, based on clinical and polysomnographic
data.18 However the available data is diverse and conflict-
ing, with no clear predictive factors emerging.19e22
Similarly we have previously shown that it is not
possible, from baseline data to predict which patients
offered CPAP will opt to continue it long-term after a two-
week trial. However we found that using data available at
the end of a two-week trial we could predict those patients
who would continue to use it satisfactorily at one year.23
Other studies have also shown that short term compliance
with CPAP can predict long term compliance.21,24 In our
study a logistic regression model indicated that nightly
mean CPAP use during the loan period and a simple satis-
faction score accurately defined continuing CPAP and
"satisfactory" CPAP use at one year. For patients with low
CPAP usage and no symptomatic improvement during the
trial period the addition of baseline AHI and difference of
Epworth score between baseline and the end of the loan to
the regression equation improved the predictive value of
the model but only slightly. The models were much less
reliable at identifying patients who would not use CPAP, as
some patients with a low probability of using CPAP were
actually using it “satisfactorily” at one year. We now
attempt to assess the impact of these models in a different
patient population and explore the possibility of any prac-
tical utility.
Methods
The study was conducted in the Department of Respiratory
Medicine at St. James’s University Hospital, Leeds, UK.
Diagnosis of OSAS is based upon the clinical history and
examination and confirmed by either an overnight respira-
tory variable sleep study (Embletta) or pulse oximetry.Usual demographic information, Epworth Sleepiness Score
Index (ODI) or 4% dip rate for oxygen saturations were
recorded.
The decision to offer patients a trial of CPAP depends on
a balance between the severity of the sleep disordered
breathing, the patient’s symptoms and their impact upon
quality-of-life. Broadly speaking patients with significant
sleep disordered breathing (AHI or ODI greater than or
equal to 30 events per hour) are offered the trial of CPAP
whether or not they perceived that they had significant
symptoms, whereas patients with AHI or ODI less than 30
events per hour were offered a trial of CPAP if they had
symptoms which had an impact on quality-of-life and
daytime function. Other factors such as occupation, miles
driven per year, marital disharmony, potential for benefit
from other interventions (eg. alcohol avoidance, weight
reduction, relief of nasal obstruction), patient’s preference
and expectation also influence the decision. CPAP was
usually offered as the first choice treatment.
Patients who accepted the offer of a CPAP trial were
loaned a smart CPAP (ResMed Autoset Spirit S7 or S8) device
for a two-week home trial in a one to one appointment of
45 min with a specialist nurse. They were fitted with an
appropriatemask andhead gear andexplained the rationale,
benefits and possible side effects of CPAP in detail. They
were provided with information leaflets and troubleshooting
tips. They are encouraged to contact the team in case of any
problems. At theendof the twoweeks theywere reviewedby
the nurse specialist in a 30 min appointment. They
completed an Epworth score and a five point satisfaction
score (“much better” to “much worse”) of how they felt
during the two week period. Themean overnight use and the
AHI while on CPAP were downloaded from the machine. The
AHI estimated by Auto-titrating CPAP has been shown to
correlate with AHI from polysomnography.25,26 At this
consultation patients were asked whether they wished to
continue CPAP long-term. Occasionally patients were
offered an extension of the two-week period or a second trial
either because they had developed a problem which
compromised their ability to use CPAP (for instance upper
respiratory tract infection) or if they had severe symptom-
atic disease, had struggled with CPAP initially and were
willing to have another try. During the second trial patients
were offered any of the following: a different mask,
a humidifier or with the machine set with a lower maximum
allowable pressure, as deemed appropriate.
For those accepting CPAP a machine (fixed pressure
CPAP machine with setting based on pressures recorded by
auto-titrating machine) was issued and the patient fol-
lowed up either in person or by telephone at 2 months.
Patients were also encouraged to contact the nurse
specialists in case of any problems. Those with low machine
use and/or poor symptom control had further inputs which
included change of mask type, addition of a humidifier,
adjustment of CPAP pressure or further education. Patients
with residual sleepiness, despite adequate CPAP use, noted
at any consultation had a CPAP machine download and/or
check sleep study performed while using CPAP and any
issues identified corrected.
Patients on CPAP were then reviewed in a yearly CPAP
users’ clinic at which point the assessment included
Figure 1 CPAP compliance prediction table derived from the
prediction equation.
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mean nightly use of the machine, calculated by dividing the
total recorded hours of use by the number of days since the
last reading.
Equations and analysis
The first equation derived from the regression analysis
included average hourly use during the trial and patients’
response to how they feel after the trial. The second
equation included the above with in addition diagnostic and
treatment ESS and diagnostic AHI. Both the equations have
been converted to a simple Excel based tool for ease of
use. In these models a probability score of 50% was sug-
gested as the cut off value, above which it was predicted
that a patient will use CPAP satisfactorily at one year.
Patients using the CPAP machine for more than 2 h per night
on average were considered to have "satisfactory" levels of
use. This 2 h cut off is derived from the original study.23 The
analysis was rerun using cut offs of 3 and 4 h. The actual
equations are shown in Table 1. The Excel based tool and
instructions are provided as an online supplement, and
a simple summary table with various combination of
average overnight usage and patients’ responses is provided
in Fig. 1.
All the patients who had undergone a trial of CPAP in
2007 were identified from the sleep services database using
only a numerical identifier and thereby all data was
completely anonymised. The equations were applied to
come up with a predicted probability score. A score above
50% should predict satisfactory use at one year and this was
compared with the actual outcomes to calculate the
sensitivity, specificity and predictive values of the models.
The equations had not been used to inform the decision as
to whether CPAP should be issued or not.
Logistic regression was carried out in an attempt to
predict satisfactory use at 1 year with baseline demo-
graphic and polysomnographic information as was per-
formed in the original study.23 The outcome variables were
“using CPAP satisfactorily” and “not using CPAP satisfac-
torily” at one year. The independent variables were age,
sex, BMI, diagnostic AHI and ESS. This was to validate the
original findings in a different population.
Overnight usage at the time of trial and at one year was
correlated using Pearson’s coefficient.Table 1 The regression equations.
Equation (1) Equation
Probability of using satisfactorily at 1 year Z X/(1 þ X)
Where X Z EXP (0.9655 þ H * 0.4984 þ R)
Probabil
Where Y
H Z Average overnight usage in hours during
the 2 week trial period
R Z Response to the question “How do you feel
after CPAP trial?” Much Worse Z 9.2373,
Worse Z 10.1182, Same Z 11.9076,
Better Z 1.0157, Much better Z 0
H Z Ave
R Z Res
Much W
Better Z
DA Z D
DE Z D
“13e18
TE Z Tr
“13e18Statistical analysis was carried out using GraphPad
Prism 5 and SPSS 17 software. As anonymised data were
used for this study, formal ethical approval was deemed
unnecessary by the local NHS Research Ethics Committee.
Results
In 2007 a total of 502 patients with various severities of OSA
were referred for a trial of CPAP. There was sufficient
information on 448 patients [346 (77%) males, Age 53  11
years, BMI 35  8 kg/m,2 ESS 14  4, AHI 37  24, ODI
43  26] to apply the first equation. A further 41 patients
were excluded from the analysis due to various factors
including moving to a different area, incomplete 1 year
data, planned temporary CPAP for peri-operative use only.
Of the 407 patients 333 (82%) were issued with a CPAP
machine and 74 (18%) declined long term CPAP.
A regression analysis was performed utilizing the base-
line information, prior to the commencement of the CPAP
trial, in an attempt to predict who would decline CPAP
option after the 2 week trial and also to predict 1 year
compliance. The analysis showed that it is not possible to
predict either of them, confirming the findings from the
original study.
At one year, 270 (81%) patients were using CPAP for at
least 2 h while 256 (76%) were using it for at least 3 h and
236 (70%) had a usage of more than 4 h per night. One
hundred and eighty eight (56%) and 53% patients had
a usage of more than 5 and 6 h respectively. The patients
using CPAP at least for 2 h at 1 year were more likely to be(2)
ity of using satisfactorily at 1 year Z Y/(1 þ Y)
Z EXP(1.1987 þ 0.7555 *H þ 0.0304 * DA þ R þ DE þ TE)
rage overnight usage in hours during the 2 week trial period
ponse to the question “How do you feel after CPAP trial?”
orse Z 8.637, Worse Z 8.8342, Same Z 11.18,
1.2612, Much better Z 0.
iagnostic AHI (or ODI in case of oxymetry)
iagnostic ESS. ESS “0e6” Z 5.3914, “7e12“ Z 4.9789,
“ Z 5.5893, “ 19e24” Z 0
eatment ESS. ESS “0e6” Z 2.743, “7e12“ Z 3.7408,
“ Z 0.6703, “19e24” Z 0
Figure 2 Outcomes at 1 year using the first equation (patient numbers are proportional to the area of text boxes, * Z Excluded
due to insufficient information, # Z Using CPAP satisfactorily at 1 year).
Table 2 Sensitivities, specificities, positive predictive
values (PPV) and negative predictive values (NPV) for
equations (1) and (2) using different definition for satis-
factory usage.
Average overnight use
2 h 3 h 4 h
Equation (1)
Sensitivity 91 92 95
Specificity 24 25 27
PPV 84 80 76
NPV 39 52 71
Equation (2)
Sensitivity 79 80 82
Specificity 32 34 35
PPV 84 80 76
NPV 25 33 45
Prediction equation for CPAP compliance 939males (pZ 0.004, ORZ 2.3), had higher diagnostic ODI/4%
dip rate (46  26 vs 36  25, p Z 0.01), showed a greater
drop in ESS (change 8  6 vs 6  6, p Z 0.005) and higher
overnight usage during the trial period (5.9  1.4 vs
4.9  1.5, p < 0.001). There was a strong correlation
between overnight CPAP usage during the trial period and
at one year (Pearson’s r Z 0.55, p < 0.001).
Fig. 2 shows the outcomes of the CPAP trials in 2007 and
how the patients scored on prediction equation (1) (applied
retrospectively).
All 295 patients with a score of 50%, had been issued
with CPAP. 247 (84%) patients, (baseline ESS 15  4, AHI
40  26, ODI 44  26) were using CPAP “satisfactorily” at 1
year. The average CPAP usage at 1 year for patients with
scores of 50% and below 50% were 5.4  2.5 and 4  2.1 h
respectively.
Of the 112 patients with a score below 50%, 74 had
declined CPAP. 38 patients had accepted CPAP treatment &
23 (60%) patients (ESS 15  5, AHI 40  21, ODI 45  23)
were still using CPAP “satisfactorily” at 1 year. This
difference in CPAP compliance at 1 year between patients
with scores below and above 50 was highly significant (Chi
square p < 0.001).
The sensitivity & specificity of the first equation were
91% & 24% respectively. The Positive Predictive Value was
84% with a Negative Predictive Value of 39%. The sensitivity
of this equation in identifying compliers in the original
study was 94%.
The second equation, despite utilizing more information
was not superior to the first equation. If the definition of
satisfactory usage was changed to 3 or 4 h, the negative
predictive value ie. the likelihood of predicting who will notbe using CPAP above a certain threshold goes up. However
the sensitivity and specificity remains similar. (Table 2).
Discussion
It is important not only to know which patients are likely to
be compliant with CPAP treatment in the long term but
also who are likely to have problems. Predicting short and
long term compliance with CPAP from the initial demo-
graphic, clinical and polysomnographic data is difficult.20
In our original study there was no significant difference
940 D. Ghosh et al.between the groups who accepted CPAP after initial trial
period and who declined or between the groups of satis-
factory users and non users at one year in terms of age.
Collen et al found only the use of a sedative/hypnotic
during CPAP titration (p < 0.0005) and higher age
(p Z 0.02) were associated with better short term
compliance.18 Poulet et al could accurately predict in 85%
patients who would be compliant in the short term using
psychological variables.27 Other studies have shown con-
flicting evidence regarding impact of age and gender on
long term compliance.19,28 A high AHI has been shown to
correlate positively with long term compliance.22,29,30 In
our study the diagnostic ODI was significantly higher in the
compliant group but only in univariate analysis. In a more
recent study by Kohler et al, ODI was found to be the only
predictor of long term compliance after multivariate
analysis.31 However this study did not include any patient
satisfaction score like ours which could potentially have
been better in predicting compliance. Our second equation
which included AHI was not any superior to the first
equation in predicting compliance in the validation cohort.
High ESS did not correlate with short or long term
compliance, similar to our previous study and other pub-
lished data.18,22,31
We have previously shown that data obtained after a 2
week trial can predict compliance at one year.23 A small
number of patients might choose not to use CPAP long term
because of symptomatic improvement due to other causes
like losing weight, tonsillectomy etc. This group will not be
identified by these models but is unlikely to influence the
model due to very small numbers. We have now validated
this equation in a different population which has not been
done before for any prediction models. A score above 50 in
the first equation predicted with a high level of confidence,
which patients would be using the CPAP at 1 year. The
majority of the patients who scored below 50 declined to
have CPAP. However if they opted to accept CPAP treat-
ment, 60% continued to use “satisfactorily” at 1 year. But
this is significantly lower than the group with score above
50 (84%, p Z 0.0004). These data, and those from other
studies, confirm that it is reasonable to offer all patients
with a high ODI/AHI a trial of CPAP regardless of their
symptom burden. Our practice of offering CPAP to anybody
with AHI/ODI > 30 is supported by recent data from Kohler
et al where the adherence rate at 10 years was 79% for
patients with ODI >30e60.31 We now know that long term
compliance is vital not only for symptomatic improvement
but also for effects on cardiovascular morbidities like
hypertension, diabetes, stroke, etc.17,32,33 However
currently we do not have enough evidence to offer CPAP to
patients with less severe OSAS who do not have excessive
day time somnolence.
Various interventions have been shown to improve long
term compliance. It is important to identify the issues that
might affect compliance and address them as far as prac-
ticable. Common issues include difficulty with masks, nasal
or pharyngeal problems and lack of subjective improve-
ment.28 Weekly phone calls during the first month of CPAP
usage or use of a short educational video during the initial
titration improved the compliance compared to standard
written information.34,35 Extra early support improved re-
attendance rates at 1, 6 and 12 months.36 A compliancerate of >85% at 6 months was achieved by an intensive
follow up and “troubleshooting” regime.37 There are other
newer methods being tried to improve compliance which
include use of Eszopiclone during initial trial, Cognitive-
Behaviourally informed and Motivational interventions and
telemonitoring.38e41
All these interventions are simple but labour intensive. It
is not feasible to provide intensive follow up regimes for all
patients. Our validated prediction equation can identify
patients who are less likely to persist with CPAP long term
and might therefore benefit more from these regimes and
help to prioritize resources accordingly. The simple Excel
based tool makes it easy to use on a day to day basis.
Eighteen percent (74/407) of our patients declined to
continue CPAP after the initial two week trial; other
studies report that around 30% of patients have either
declined longer term CPAP or are not using it at 1
month.27,42 Overall 81% of our patients who were issued
with a CPAP were using it for at least 2 h/night and 70% for
4 h at one year. Our mean overnight use over the first year
was 6.0 ( 1.8) hours. This is comparable to the recent
data published for long term compliance by Kohler et al
and other previous studies.29,31,43 Therefore our pop-
ulation of patients using CPAP is likely to be similar to
those in other studies and our results generalisable. It is
worth noting that compliance and adherence rate of CPAP
treatment in general is higher or comparable to other
therapies in respiratory medicine. Adherence to inhaler
therapy in COPD varies between 40 and 60% in the general
population. Percentage of patients using the inhalers
properly is even lower.44,45 Even in the research setting
adherence to inhalers is reported as 79%.46 Measuring
compliance for CPAP is easier, and therefore more likely to
be accurate, than medical therapies with the ability to
download data from the machines.
In summary, it is important to identify patients who are
likely to benefit from long term CPAP but are less likely to
adhere to treatment. Potential benefits of long term
adherence are not only reduced symptoms and improved
quality of life, but also potentially reduced cardiovascular
morbidity and mortality. This simple tool which has now
been validated can identify this subset of patients who
might benefit from more intensive follow up, particularly if
they have severe OSA or many symptoms. The simplicity of
the tool makes it an attractive practical option in busy
clinics.
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